Your browser doesn't support javascript.
loading
Treatment of segmental continuous hypertrophic myokymia of the limb with botulinum A toxin.
Yousaf, Muhammad Ismail Khalid; Ghani, Mohammad Ravi; D'Aguiar Rosa, Talita; Holiday, Victoria; Brown, Martin; Hedera, Peter.
Afiliação
  • Yousaf MIK; Department of Neurology, University of Louisville School of Medicine, Louisville, KY, USA.
  • Ghani MR; Department of Neurology, University of Louisville School of Medicine, Louisville, KY, USA.
  • D'Aguiar Rosa T; Department of Neurology, University of Louisville School of Medicine, Louisville, KY, USA.
  • Holiday V; Department of Neurology, University of Louisville School of Medicine, Louisville, KY, USA.
  • Brown M; Department of Neurology, University of Louisville School of Medicine, Louisville, KY, USA.
  • Hedera P; Department of Neurology, University of Louisville School of Medicine, Louisville, KY, USA.
SAGE Open Med Case Rep ; 10: 2050313X221137214, 2022.
Article em En | MEDLINE | ID: mdl-36406303
ABSTRACT
Myokymia is defined as fluctuating hyperexcitability of muscle fibers caused by repetitive spontaneous contraction of motor units. Myokymia is generally benign with self-resolution, although symptomatic treatment with benzodiazepines, anticonvulsants, and muscle relaxants can be used. Botulinum toxins can also be utilized, although they are mostly used for symptomatic facial myokymia. Here, we report two patients who developed continuous myokymia, resulting in secondary hypertrophy, stiffness, and discomfort in the affected muscles. The first patient had a history of a tethered spinal cord and developed continuous myokymia in the S1 and S2 radicular regions of the left leg. The second patient underwent radiation therapy for lung cancer and developed brachial plexopathy with abnormal activity in the muscles supplied by the musculocutaneous nerve in the right arm. Both patients experienced sleep disturbance, focal discomfort, and restlessness. The anticonvulsants and muscle relaxants were ineffective. Chemodenervation with botulinum A toxin was initiated using either onabotulinumtoxinA or abobotulinumtoxinA. Both patients experienced a substantial reduction in myokymia, with ongoing reversal of muscle hypertrophy and significant improvement in reported subjective symptoms. Treatment with botulinum toxins can be highly effective in patients with symptomatic segmental continuous hypertrophic myokymia and may be considered first-line therapy.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: SAGE Open Med Case Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: SAGE Open Med Case Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos